Phase 1 Type 1 Diabetes Trial, Recruiting NCT07590193 Sponsor: Amgen Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Phase 1 Type 1 Diabetes Trial, Recruiting

NCT07590193
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For Parts A and B:

  • People between 18 and 65 years of age
  • People who are generally in good health with no significant medical conditions

For Part C:

  • People between 40 and 75 years of age
  • People who have been diagnosed with Type 2 diabetes

Who may not be able to join:

For Parts A and B:

  • People who have a history of low blood pressure, fainting, or dizziness when standing up
  • People whose blood pressure readings are above a certain level (top number above 140 or bottom number above 90)

For Part C:

  • People whose blood sugar control measure (a test called HbA1c) was above 10% in the last 3 months
  • People who have a history of low blood pressure, fainting, or dizziness when standing up
  • People whose blood pressure readings are above a certain level (top number above 160 or bottom number above 100)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: MD, Amgen

Phone: 866-572-6436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
11 June 2026
Est. completion
2 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Treatment-Emergent Adverse Events (TEAEs); Number of Serious Adverse Events (SAEs); Number of Adverse Events Leading to Study Discontinuation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov